-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Researchers at Karolinska Institutet in Sweden recently found that a novel immunotherapy against hepatitis B and D viruses has shown good results
Chronic infections with hepatitis B virus (HBV) and hepatitis D virus (HDV) are the leading causes of
Hepatitis D is present only in patients with co-infection with hepatitis
For these reasons, researchers at Karolinska Institutet are developing a new treatment that hopes to produce a lasting therapeutic response to both viruses
This therapy consists of two parts and is designed to affect the immune system
Newly published research suggests that this therapy can protect cultured cells from HBV and HDV infection
In addition, the antibodies produced by treating mice were able to protect mice carrying human liver cells from simultaneous infections
"These results are promising," said Matti Sällberg, a professor in the Department of Laboratory Medicine at Karolinska Institutet and one
"This study shows that this is a viable pathway and encourages us to continue to develop methods for human treatment.
This therapy was developed
The study was supported by funding
Search for the original text
Burm R, Maravelia P, Ahlen G, et alNovel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infectionsGut Published Online First: 17 August 2022.
